Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A crystal ball for ICU infections? new model aims to forecast who survives resistant bacteria

NCT ID NCT07749508

Knowledge-focused Sponsor: Fundacion SEIMC-GESIDA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study aims to develop a predictive model for mortality in critically ill patients who carry multidrug-resistant gram-negative bacteria (MDR-GNB). Researchers will follow about 1,500 adults in intensive care units (ICUs) who are colonized with these bacteria, tracking their infections, complications, and outcomes. The goal is to identify factors that help predict which patients are at highest risk of dying, potentially guiding more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a tool to identify which ICU patients with resistant bacteria are at highest risk, potentially guiding more aggressive or earlier treatment.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The predictive model may not be accurate enough for all patients or hospital settings, and it may not directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All the patients entering in ICU

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥18 years * Have given informed consent. Exclusion Criteria: * Patients who do not agree to participate in the study * Admission to the ICU \< 24 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multi-resistant gram-negative bacteria cause infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gram-negative bacterial infections viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multi-resistant gram-negative bacteria cause infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, Madrid, 28046, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.